764 Background: With the evolving treatment (tx) landscape in la/mUC, patient (pt) clinical characteristics are increasingly important when selecting systemic anticancer tx. This study describes pt characteristics, tx patterns, and outcomes by tumor burden pts with la/mUC treated avelumab 1LM following 1L platinum-based chemotherapy (PBC) no progressive disease (PD). Methods: In this noninterventional retrospective study, were identified using Flatiron Health’s electronic health record...

Avelumab first-line maintenance (1LM) is approved for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who do not have disease progression after platinum-based chemotherapy (PBC). This retrospective study describes real-world treatment patterns and clinical outcomes in la/mUC initiated (1L) systemic treatments, including avelumab 1LM, within iKnowMed, the US community oncology electronic health records database, between 1 December 2019 30 November 2023 followed...

605 Background: Avelumab 1LM is recommended in international guidelines for pts with la/mUC and disease control after 1L platinum-based chemotherapy (PBC). This study describes the treatment landscape FDA approval of avelumab June 2020 by examining pt characteristics, patterns sequencing, rw outcomes treated 1LM. Methods: noninterventional retrospective identified who received US using data from Flatiron Health’s electronic health record database. Pts aged ≥18 y ≥2 visits on/after Jan 1,...

11 Background: In 2023 in the US, 82,290 new cases of bladder cancer and 16,670 related deaths were estimated. Prior analyses assessing economic burden la/mUC current evolving treatment landscape have been limited. This study aimed to estimate direct medical costs treating patients with la/mUC, from US Medicare commercial perspectives. Methods: A cost model was developed annual care eligible for 1L platinum-based chemotherapy (PBC) 2023. Costs (2023 USD)—including drug acquisition...

e16552 Background: Recent drug approvals in the 1L treatment (tx) setting have expanded options for pts with la/mUC. It is important to understand economic burden of these novel therapies within current tx landscape. This study estimated first-year cost care US from a Medicare and commercial payer perspective la/mUC treated following tx: enfortumab vedotin (EV) + pembrolizumab (PEM) platinum-eligible pts, nivolumab (NIV) platinum-based chemotherapy (PBC) cisplatin-eligible PBC or without...

e16621 Background: In June 2020, avelumab 1LM was approved in the US for pts with la/mUC without progressive disease (PD) after 1L platinum-based chemotherapy (PBC). This rw study describes pt characteristics, tx patterns, and outcomes who received 1LM. We report exploratory analyses by baseline metastatic site. Methods: A retrospective cohort of diagnosed (T4b, N2/3, and/or M1) systemic approval identified from deidentified records Tempus database. Pts no evidence PD completing PBC were...

e16551 Background: Current standard-of-care first-line (1L) tx for la/mUC includes platinum-based chemotherapy (PBC) followed by avelumab 1L maintenance (1LM) in pts without disease progression or immuno-oncology (IO) monotherapy platinum-ineligible pts. However, not all receive guideline-based care. This study examines rw patterns and overall survival (OS) with receiving systemic the US, post FDA approval of 1LM June 2020. Methods: retrospective used The US Oncology Network (iKnowMed) EHR...

For patients with locally advanced/metastatic urothelial carcinoma (la/mUC), first-line (1L) treatment platinum-based chemotherapy (PBC) followed by avelumab 1L maintenance (1LM) is a recommended therapy per guidelines in without disease progression. However, contemporary real-world (rw) data among receiving this are necessary to understand clinical outcomes and optimal sequencing. This retrospective cohort study analyzed rw patterns outcomes, including overall survival (rwOS)...

4567 Background: Standard of care has been established as 1L PBC followed by avelumab maintenance (1LM) in eligible pts based on the JAVELIN Bladder 100 trial (NCT02603432) which showed that 1LM significantly prolonged overall and progression-free survival (OS, PFS) with aUC no disease progression after PBC. Contemporary robust real-world (rw) data are limited treated PBC; however, because response status to determines eligibility, it is critical understand rwR rates. This study aimed assess...

572 Background: Platinum-based chemotherapy (PBC) is standard first-line (1L) treatment (tx) for patients (pts) with la/mUC. On June 30, 2020, avelumab was approved in the US as 1L maintenance (1LM) pts without disease progression following PBC. Other novel agents such enfortumab vedotin were recently second-line (2L) or later tx. Little known about how to incorporate these into optimal tx sequencing approach. This real-world (RW) study describes characteristics and patterns of Methods: A...

BACKGROUND: Among patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC), incidence of brain metastases (BMs) is relatively high and increasing. Despite the unmet need for HER2+ MBC BMs, real-world data on treatment patterns outcomes these are limited. OBJECTIVE: To compare overall survival (OS) among without BMs in United States. METHODS: This was a retrospective cohort study which adults diagnosed between January 1, 2016, May 31, 2019, were...

e13514 Background: Platinum-based chemotherapy (PBT) followed by avelumab (AVE) as first-line (1L) maintenance for patients with nonprogressive disease (PBT ± AVE) is the standard of care in la/mUC. This study compared overall survival (OS) and cost-effectiveness tx sequence PBT AVE enfortumab vedotin (EV) or other therapies, including immuno-oncology (IO), second line (2L; ie, + 2L EV/IO EV/IO) vs 1L EV pembrolizumab (PEM) PBT-eligible (PBTp) from a US commercial payer perspective. Methods:...

393 Background: Avelumab 1LM tx is approved in the US for pts with la/mUC who do not have disease progression after platinum-based chemotherapy (PBC). The landscape evolving due to recent approvals of newer therapies la/mUC. This study examines rw patterns, sequencing post avelumab 1LM, and OS initiated 1L community oncology setting. Methods: retrospective cohort used Oncology Network (iKnowMed) EHR database. included adult (≥18 years) initiating (index date) between Dec 1, 2019, Nov 30,...

390 Background: Avelumab 1LM is a standard of care for pts with mUC that has not progressed after 1L platinum-based chemotherapy (PBC). Immuno-oncology (IO) monotherapy considered in who are ineligible to receive PBC. Recently approved tx options include enfortumab vedotin + pembrolizumab and nivolumab gemcitabine/cisplatin. This US retrospective study examined pt characteristics, patterns, clinical outcomes among receiving tx, including avelumab 1LM. Methods: Pts (bladder cancer; stage IIIB...

Abstract Background The treatment landscape for locally advanced/metastatic urothelial carcinoma (la/mUC) has evolved. This study examined US prescribing patterns and clinical decision-making first-line (1L) maintenance (1LM) treatment. Materials Methods US-based oncologists (N = 150) completed an online survey on patient demographics, practice patterns, important factors considered in 1L/1LM selection. Multivariable logistic regression was used to assess associated with more vs less...

4595 Background: The treatment (tx) landscape for la/mUC has evolved with the use of immunotherapy (IO) platinum-refractory as well first-line (1L) maintenance therapy (1LM). This cross-sectional survey explored practice patterns 1L tx/1LM and clinical decision-making. Methods: Community/academic US oncologists (n = 150) completed an online (Sept-Oct 2021) on demographics, tx, 1LM use, attributes in tx selection/1LM factors associated use. Physicians were dichotomized into 4 pre-specified...

Abstract Background: Human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) is associated with increased clinical and economic burden. Patients brain metastases (BM) have significantly worse outcomes, however, limited data exist evaluating healthcare resource utilization (HCRU) among HER2+ MBC patients BM. Objective: To describe treatment patterns HCRU or without who received HER2-targeted therapy using retrospective claims data. Methods: Data obtained from...